Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases.
Can Respir J
; 2021: 9099802, 2021.
Article
en En
| MEDLINE
| ID: mdl-34887972
ABSTRACT
Background:
Serum Krebs von den Lungen-6 (KL-6) measurement is widely used to assess disease activity or prognosis in patients with interstitial lung diseases (ILDs). However, the clinical differences between high and low serum KL-6 levels at the time of acute exacerbation (AE) of ILD are not well known.Methods:
Clinical parameters including age, sex, Charlson Comorbidity Index score (CCIS), blood biomarkers, high-resolution CT findings, and disease mortality were retrospectively compared between high and low KL-6 (cutoff value 1000 U/mL) patients at the time of diagnosis of AE of ILDs.Results:
Thirty-eight high serum KL-6 and 57 low serum KL-6 patients were included. There was no significant difference in 6-month mortality between them (P = 0.685), whereas serum lactate dehydrogenase was a significant predictor of 6-month mortality in the high serum KL-6 patients (odds ratio (OR) 1.006; 95% confidence interval (CI) 1.003-1.009; P < 0.001), and CCIS (OR 1.502; 95% CI 1.242-1.838; P < 0.001) and sex (OR 5.751; 95% CI 1.121-105.163; P = 0.033) were significant predictors in low serum KL-6 patients. In addition, the incidences of congestive heart failure, symptomatic chronic pulmonary disease, cerebrovascular disease, and second metastatic solid tumours were significantly higher in nonsurvivors with low serum KL-6 than in other groups (P < 0.05).Conclusions:
The clinical features in patients with AEs of ILDs may differ depending on the serum KL-6 level, and clinicopathological examination according to this subtyping guided by the serum KL-6 level is essential.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Pulmonares Intersticiales
Tipo de estudio:
Observational_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Can Respir J
Año:
2021
Tipo del documento:
Article
País de afiliación:
Japón